- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06769048
Een onderzoek om verschillende doses BI 1584862 te testen bij mensen met een duidelijke vorm van leeftijdsgebonden maculaire degeneratie (AMD), genaamd geografische atrofie
JADE: Fase II-onderzoek bij patiënten met geografische atrofie: een gerandomiseerde, dubbelblinde, placebogecontroleerde dosisbepalende studie om de werkzaamheid en veiligheid van BI te evalueren 1584862
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.
Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Arecibo, Puerto Rico, 00612
- Emanuelli Research & Development Center
-
-
-
-
Arizona
-
Gilbert, Arizona, Verenigde Staten, 85297
- Associated Retina Consultants
-
Phoenix, Arizona, Verenigde Staten, 85020
- Associated Retina Consultants, Ltd.
-
Phoenix, Arizona, Verenigde Staten, 85050
- Cameron Ria, LLC
-
Scottsdale, Arizona, Verenigde Staten, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Beverly Hills, California, Verenigde Staten, 90211
- Retina-Vitreous Associates Medical Group
-
Glendale, California, Verenigde Staten, 91204
- Global Research Management
-
Huntington Beach, California, Verenigde Staten, 92647
- Retina Associates of Southern California
-
Modesto, California, Verenigde Staten, 95356
- Retinal Consultants Medical Group, Inc
-
Mountain View, California, Verenigde Staten, 94040
- Northern California Retina Vitreous Associates MedicalGroup, Inc.
-
Newport Beach, California, Verenigde Staten, 92663
- Eye Research Foundation
-
Poway, California, Verenigde Staten, 92064
- Retina Consultants of San Diego
-
Sacramento, California, Verenigde Staten, 95825
- Retinal Consultants Medical Group
-
Walnut Creek, California, Verenigde Staten, 94598
- Bay Area Retina Associates - Walnut Creek
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80222
- Retina Specialists of Colorado Research, LLC
-
-
Connecticut
-
Greenwich, Connecticut, Verenigde Staten, 06830
- Coastal Eye Surgeons
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32605
- Vitreo Retinal Associates - Gainesville
-
Miami, Florida, Verenigde Staten, 33143
- MedEye Associates
-
Pinellas Park, Florida, Verenigde Staten, 33782
- Eye Associates of Pinellas
-
Stuart, Florida, Verenigde Staten, 34994
- East Florida Eye Institute
-
Winter Haven, Florida, Verenigde Staten, 33880
- Center for Retina and Macular Disease
-
-
Georgia
-
Augusta, Georgia, Verenigde Staten, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Park, Illinois, Verenigde Staten, 60304
- Illinois Retina Associates - Oak Park
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40206
- The Eye Care Institute
-
-
Maryland
-
Hagerstown, Maryland, Verenigde Staten, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
Columbia, Missouri, Verenigde Staten, 65212
- University of Missouri Health System
-
-
New Jersey
-
Teaneck, New Jersey, Verenigde Staten, 07666
- NJRetina
-
-
Oregon
-
Eugene, Oregon, Verenigde Staten, 97401
- Verum Research, LLC
-
Portland, Oregon, Verenigde Staten, 97221
- Retina Northwest
-
Portland, Oregon, Verenigde Staten, 97225
- EyeHealth Northwest
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Mid Atlantic Retina - Wills Eye Hospital
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29414
- Charleston Neuroscience Institute - Charleston
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Tennessee Retina
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78750
- Austin Clinical Research, LLC
-
Beaumont, Texas, Verenigde Staten, 77707
- Retina Consultants of Texas - Beaumont
-
Dallas, Texas, Verenigde Staten, 75231
- Retina Foundation of the Southwest
-
Plano, Texas, Verenigde Staten, 75024
- Red River Research Partners, LLC - Plano
-
San Antonio, Texas, Verenigde Staten, 78240
- Retinal Consultants of San Antonio
-
Schertz, Texas, Verenigde Staten, 78154
- Retina Consultants of Texas - Schertz
-
The Woodlands, Texas, Verenigde Staten, 77384
- Retina Consultants of Texas-The Woodlands-67575
-
-
Virginia
-
Falls Church, Virginia, Verenigde Staten, 22042
- Emerson Clinical Research Institute
-
Lynchburg, Virginia, Verenigde Staten, 24502
- Piedmont Eye Center
-
-
Washington
-
Bellevue, Washington, Verenigde Staten, 98004
- Pacific Northwest Retina
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
-
Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:
- If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm^2
- At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
- The foveal center point must not be involved in any atrophic lesion
- Lesion(s) must reside completely within the FAF image
-
Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).
-
Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.
-
Age ≥50 years.
-
Men must be willing and able to use contraception (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. A female participant is eligible if she is not a woman of childbearing potential.
-
Signed informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation
Exclusion criteria:
-
Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.
-
Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.
-
Previously received an investigational medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.
-
Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:
- uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
- clinically significant diabetic retinopathy or maculopathy in the opinion of the investigator
- history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
- anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
- other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
-
Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:
- put the participant at risk because of participation in the study
- influence the results of the study
- cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
-
Known hypersensitivity to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.
-
Active intraocular inflammation in the study eye.
-
Active infectious conjunctivitis in either eye. Further exclusion criteria apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo-matching BI 1584862
|
Placebo-matching BI 1584862 |
|
Experimenteel: BI 1584862 dosis 1
|
BI 1584862 |
|
Experimenteel: BI 1584862 dosis 2
|
BI 1584862 |
|
Experimenteel: BI 1584862 dosis 3
|
BI 1584862 |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye
Tijdsspanne: Up to week 50.
|
mm is millimeters. |
Up to week 50.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Optreden van TEAES vanaf de toediening van het geneesmiddel tot week 52
Tijdsspanne: Tot week 52.
|
Tot week 52.
|
|
|
Verandering ten opzichte van de uitgangswaarde in gedeeltelijke verzwakking als percentage van de ellipsoïde zone (EZ) in het maculaire gebied met een dikte <20 microgram (μm) tot week 50, beoordeeld door volumetrische optische coherentietomografie (OCT) in het onderzoeksoog
Tijdsspanne: Tot week 50.
|
Tot week 50.
|
|
|
Verandering ten opzichte van de uitgangswaarde in het vierkantswortel-getransformeerde geografische atrofiegebied (GA), zoals gemeten door fundus autofluorescentie (FAF) in week 50 (uitgedrukt in mm) in het onderzoeksoog
Tijdsspanne: Bij baseline en in week 50.
|
Bij baseline en in week 50.
|
|
|
Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye
Tijdsspanne: Up to week 50.
|
EZ stands for ellipsoid zone. OCT stands for optical coherence tomography. |
Up to week 50.
|
|
Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye
Tijdsspanne: Up to week 50.
|
GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters. |
Up to week 50.
|
|
Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50
Tijdsspanne: Up to week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
Up to week 50.
|
|
Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye
Tijdsspanne: At baseline and at week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
At baseline and at week 50.
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1484-0005
- U1111-1309-9115 (Register-ID: WHO International Clinical Trials Registry Platform (ICTRP))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD-tijdsbestek voor delen
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD-toegangscriteria voor delen
For study documents - upon signing of a 'Document Sharing Agreement'.
For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .